PortalPublikationenBridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymp...

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL

Standard

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL. / Gagelmann, Nico; Gribben, John; Kröger, Nicolaus.

The EBMT/EHA CAR-T Cell Handbook. Hrsg. / Nicolaus Kröger; John Gribben; Christian Chabannon; Ibrahim Yakoub-Agha; Hermann Einsele. 1. Aufl. Cham : Springer International Publishing, 2022. S. 123-125.

Publikationen: SCORING: Beitrag in Buch/Sammelwerk › Kapitel › Forschung

Harvard

Gagelmann, N, Gribben, J & Kröger, N 2022, Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL. in N Kröger, J Gribben, C Chabannon, I Yakoub-Agha & H Einsele (Hrsg.), The EBMT/EHA CAR-T Cell Handbook. 1 Aufl., Springer International Publishing, Cham, S. 123-125. https://doi.org/10.1007/978-3-030-94353-0_23

APA

Gagelmann, N., Gribben, J., & Kröger, N. (2022). Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL. in N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, & H. Einsele (Hrsg.), The EBMT/EHA CAR-T Cell Handbook (1 Aufl., S. 123-125). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_23

Vancouver

Gagelmann N, Gribben J, Kröger N. Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL. in Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, Hrsg., The EBMT/EHA CAR-T Cell Handbook. 1 Aufl. Cham: Springer International Publishing. 2022. S. 123-125 https://doi.org/10.1007/978-3-030-94353-0_23

Bibtex

@inbook{2999391796b04f4ab890cae70c6c8fe2,
title = "Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL",
abstract = "While lisocabtagene maraleucel (liso-cel) is the only product that is specifically approved to treat grade 3B follicular lymphoma (FL), specifically in aggressive lymphoma indications, to date, axi-cel is the first and only approved CAR-T product for indolent NHL.",
author = "Nico Gagelmann and John Gribben and Nicolaus Kr{\"o}ger",
year = "2022",
doi = "10.1007/978-3-030-94353-0_23",
language = "English",
isbn = "978-3-030-94352-3",
pages = "123--125",
editor = "Nicolaus Kr{\"o}ger and John Gribben and Christian Chabannon and Ibrahim Yakoub-Agha and Hermann Einsele",
booktitle = "The EBMT/EHA CAR-T Cell Handbook",
publisher = "Springer International Publishing",
address = "Switzerland",
edition = "1",

}

RIS

TY - CHAP

T1 - Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL

AU - Gagelmann, Nico

AU - Gribben, John

AU - Kröger, Nicolaus

PY - 2022

Y1 - 2022

N2 - While lisocabtagene maraleucel (liso-cel) is the only product that is specifically approved to treat grade 3B follicular lymphoma (FL), specifically in aggressive lymphoma indications, to date, axi-cel is the first and only approved CAR-T product for indolent NHL.

AB - While lisocabtagene maraleucel (liso-cel) is the only product that is specifically approved to treat grade 3B follicular lymphoma (FL), specifically in aggressive lymphoma indications, to date, axi-cel is the first and only approved CAR-T product for indolent NHL.

U2 - 10.1007/978-3-030-94353-0_23

DO - 10.1007/978-3-030-94353-0_23

M3 - Chapter

SN - 978-3-030-94352-3

SP - 123

EP - 125

BT - The EBMT/EHA CAR-T Cell Handbook

A2 - Kröger, Nicolaus

A2 - Gribben, John

A2 - Chabannon, Christian

A2 - Yakoub-Agha, Ibrahim

A2 - Einsele, Hermann

PB - Springer International Publishing

CY - Cham

ER -